Format

Send to

Choose Destination
Eur J Clin Microbiol Infect Dis. 1999 Oct;18(10):743-7.

Cefotaxime-hydrolysing beta lactamases in Morganella morganii.

Author information

1
Departamento de Microbiología, Immunología y Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina.

Abstract

The frequency of enterobacterial isolates with high resistance to expanded-spectrum beta-lactam antibiotics (mainly cefotaxime or ceftriaxone) has increased notoriously in Argentina, mainly because of the spread of extended-spectrum beta-lactamases. The aim of this work was the study of extended-spectrum beta-lactamases in several Morganella morganii isolates with unusually high resistance to ceftriaxone. These strains produced at least two beta-lactamases, of apparent pIs of 5.4 and 8.2, molecular weight 23 000, well inhibited by clavulanate, compatible with a broad-spectrum beta-lactamase - perhaps TEM-1 - and an extended-spectrum beta-lactamase, respectively. The extended-spectrum beta-lactamase was identified as a CTX-M-type beta-lactamase - probably CTX-M-2 - by polymerase chain reaction, restriction profile analysis and DNA-DNA hybridisation. The remaining isolates studied produced either the broad-spectrum beta-lactamase plus the ubiquitous AmpC beta-lactamase (13 strains), or the AmpC beta-lactamase only (10 strains).

PMID:
10584905
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center